Experimental Cancer Genetics
- The FunctionScan Project – As part of these studies we are developing high-throughput methods to systematically and comprehensively identify all pathogenic alleles of cancer-associated genes. We are using techniques such as saturation genome editing at scale.
- The Genomic Atlas of Dermatopathology – While the majority of cancer deaths are associated with melanoma, a malignancy of melanocytes, there are more than 300 other skin cancer types most of which have never undergone next-generation sequencing and thus we are unaware of the driver genes in these tumours or the exposures that might promote their development. The genomic atlas of dermatopathology brings together a group of world-leading pathologists to tackle this problem.
- Combinatorial CRISPR Screening – We have a long interest in understanding cancer pathways. As part of these studies we have developed CRISPR libraries that target pairs of genes at the same time so as to identify synthetic lethal interactions and also gene redundancy. We are using these libraries to systematically screen cancer cell lines with a particular focus on metastatic melanoma, lung and pancreas as these are cancers of unmet clinical need. We are also performing a “deep dive” into the biology of several candidates to understand the basic mechanisms by which synthetic lethal gene pairs function.
- Host Regulation of Tumour Growth – As part of this work we are using the extensive collection of genetically modified mouse lines generated at the Sanger to identify genes and biological processes that moderate metastasis and tumour growth.
We have a broad interest in many aspects of cancer biology. Cancer occurs when there is an accumulation of genetic damage that confers a selective advantage on a cell, allowing it to evade normal growth control processes. Uncontrolled growth of these damaged cells ultimately results in tumour formation. While some of the key events at the molecular level that are involved in cancer formation are known, there is still much work to be done to identify those genetic changes that are important for cancer and that represent new diagnostic markers or therapeutic targets.
Dr David Adams
Senior Group Leader
Dave is a biologist whose expertise is in experimental models of human cancer. Additionally, he has a broad interest in complementary approaches such as the study of human tumour and germline genomes, and genome editing/genetic screens. He manages a team of nearly 20 scientists with diverse areas of expertise.
Previous team members
The following were also members of this team:
|Ian Sudbery (Postdoc)||Lecturer (Bioinformatics), Univ. of Sheffield, Sheffield, UK.|
|Daniela Robles (PhD student)||Group Leader, UNAM Human Genetics, Queretaro, Mexico.|
|Thomas Keane (Postdoc)||Group Leader, EBI-EMBL, UK & Prof at Univ. of Nottingham, UK.|
|Jessamy Tiffen (Postdoc)||Group Leader, Centenary Institute, Sydney, Australia.|
|Catherine Wilson (Postdoc)||Lecturer (Faculty), Cambridge University, Cambridge, UK.|
|Marcela Sjoberg (Postdoc)||Assistant Professor, University of Santiago, Chile.|
|Daniele Perna (Postdoc)||Senior Scientist, GSK, Stevenage, UK.|
|Nicola Thompson (PhD student)||Oncologist, Addenbrookes Hospital, Cambridge, UK.|
|Rebecca McIntyre (Postdoc)||Staff Scientist, Anderson Lab, Sanger Institute, Cambridge, UK.|
|Ania Migdalska (PhD student)||Lecturer, University of Exeter, Exeter, UK.|
|Jun Kong (PhD student)||Entrepreneur/Company CEO, London, UK.|
|Ruth Verstraten (RA)||Postdoc, Bowcocok Lab, Mt Sinai, NY, USA.|
|Jenny Mattison (PhD student)||Programmer, Cambridge, UK.|
|Robin van der Weide (M.Sc)||PhD Student at Utrecht, Utrecht, NL.|
|Radek Lach (PhD Student)||Postdoc at the Crick, Reddy Lab, London, UK.|
|Jorge Buendia (RA)||Programmer at the Broad Institute, Boston, USA.|
|Martin Del Castillo (PhD student)||Postdoc, Bejahti Lab, Sanger Institute, Cambridge, UK.|
|Sendu Bala (Computer Biol.)||Programmer, Sanger Institute, Cambridge, UK.|
|Marco Ranzani (Postdoc)||Senior Scientist, Artios Pharma, Cambridge, UK.|
|Ellie Dunstone (M.Sc student)||PhD student, CASM, Sanger Institute, Cambridge, UK.|
|Mamun Rashid (Computer Biologist)||Senior Data Scientist, Cambridge Epigenetics, Cambridge, UK|
|Vivek Iyer (Principal BioInformatician)||Head of Human Genetics Informatics, Sanger, Cambridge, UK.|
|Aravind Sankar (PhD student)||Postdoc, EBI, Keane Group, Cambridge, UK.|
|Bushra Abu-Helil (RA)||PhD student, Vet Medicine Group, UEA, Norwich, UK.|
|Agnes Swiatkowska (RA)||Research Assistant, CellGen, Sanger Institute, Cambridge, UK.|
|Richard Gunning (PhD student)||Programmer, Helsinki, Finland.|
|Carmen Ballesteros (RA)||Researcher at Abcam, Cambridge, UK.|
|Clara Alsinet (Postdoc)||Postdoc, Gaffney Lab, Sanger Institute, Cambridge, UK.|
|Marieke Herzog (PhD student)||Management Consultant, McKinsey & Company, London, UK.|
|Stefan Dentro (PhD student)||Postdoc, Gerstung Group, EBI, Cambridge, UK.|
|Alistair Rust (Principal Bioinformatician)||Senior Data Scientist, GSK, Stevenage, UK.|
|Theodore Whipp (Lab Manager)||Lab Manager, Cellular Genetics, Sanger Institute, Cambridge, UK.|
|Geoff Wood (Visiting Scientist)||Prof. and Co-Director, Institute for Comparative Cancer Investigation, Guelph, Canada.|
|David Wood (Visiting Scientist)||Prof. of Surgery, University of Western Australia, Perth, Australia.|
|Liezel Tamon (Visiting Scientist)||PhD student, University of Oxford, UK.|
|Katharina Strege (PhD student)||Postdoc, Griffiths Lab, Cambridge Univ, Cambridge, UK.|
|Damla Durmaz (Visiting Scientist)||Clinical Geneticist, Turkey.|
|Emanuelle Supper (Postdoc)||Product Specialist, Illumina, Cambridge, UK.|
|Natasha Karp (Statistician)||Senior Statistician, Astra Zeneca, Cambridge, UK.|
|Erini Christodoulou (Visiting scientist)||PhD student, van Dooren Lab, University of Leiden, Leiden, NL|
|Sonia Leonardelli (Visiting scientist)||PhD student, Melanoma Unit, University of Essen, Essen, Germany.|
|Gemma Turner (PhD student)||Medical writer, Glasgow, Scotland.|
Cancer Dependency Map Analytics
Cancer, Ageing and Somatic Mutation
We design algorithms and tools to identify all cancer vulnerabilities and genetic dependencies, paving the way to new therapies
Cellular Generation and Phenotyping
The Cellular Generation and Phenotyping (CGaP) core facility provides central cell biology support to the Sanger Institute, functioning as a contract ...
Cytometry Core Facility
The Cytometry Core Facility at the Wellcome Trust Sanger Institute is a dedicated scientific service offering investigators with state-of-the-art flow cytometry ...
Translational Cancer Genomics
The Translational Cancer Genomics team investigate how genetic alterations in cancer contribute to disease and impact on response to therapy.
In collaboration with our colleagues in Cellular Operations and Stem Cell Informatics, our work focuses on supporting and delivering the gene ...
High throughput gene editing
The High Throughput Gene Editing team helped to deliver the gene editing requirements of the Institute's faculty and research
Maintenance of genome stability
We work closely with David Adams' Experimental Cancer Genetics team to analyse mutations induced by DNA damage in wild-type and DDR-defective ...
Sequence Variation Infrastructure
We share interests in understanding the underlying genetics of laboratory mouse strains.
Programmes and Facilities
Open Targets is an innovative, public-private partnership that uses human genetics and genomics data at large scale for systematic drug target ...
Our group works closely with a number of other institutions and programmes. Below you can find a list of these:
We are one of the analysis groups within GenoMEL. We study the genome sequences of dozens of melanoma-prone families to search for genetic causes of their disease.
Collaborating with 3i, we generate and immunophenotype hundreds of mouse cell lines.
As part of DMDD, we study the effects of embryonic lethal mutations in mice to assign biological functions to genes.
With IMPC, we study the phenotypes of mouse knockouts in order to discover gene function.